Glycotope´s Pipeline

Using the GlycoExpress™ technology (see GlycoExpress™ and Glycooptimization) Glycotope has successfully glycooptimized a large variety of antibodies and non-antibody proteins.


The lead product GT-MAB 2.5-GEX™ is a proprietary antibody that is currently in clinical phase I in cancer indications and will progress to Phase II in H2 / 2013.

The 2nd generation antibodies CetuGEX (GT-MAB 5.2-GEX™), a glycooptimized Cetuximab and TrasGEX (GT-MAB 7.3-GEX™) are in Phase I and have recently had the IMPD filed respectively.

FSH-GEX (GT-GP 2.4-GEX™), a glycooptimized Follicle-Stimulating Hormone is Glycotope’s first non-antibody product in the clinic, Phase III is scheduled to start in Q1 / 2014.